

88 Rec'd PCT/PTO 17 APR 1998

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

IVD 925 D

U. S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/051900

INTERNATIONAL APPLICATION NO. PCT/FR96/01666	INTERNATIONAL FILING DATE October 24, 1996	PRIORITY DATE CLAIMED October 24, 1995
TITLE OF INVENTION INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM		
APPLICANT(S) FOR DO/EO/US Loïc Foulon, Georges Garcia, Claudine Serradeil-Le Gal and Gérard Valette		

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1)).
4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. has been transmitted by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. A translation of the International Application into English (35 U.S.C. 371 (c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. have been transmitted by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. A translation of the annexes (see 16 (3) and (4) below for a description of the contents of the annexes) to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
 - A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information:
 - (1) Citation of References
 - (2) Information Disclosure Statement by Applicant (Form PTO-1449)
 - (3) English translation of the claims as amended under Article 34 PCT
 - (4) English translation of pages 1, 2, 3, 4, 5, 6 as amended under Article 34 PCT

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)	INTERNATIONAL APPLICATION NO CT/FR96/01666	ATTORNEY'S DOCKET NUMBER IVD 925 D	
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5)):			
Search Report has been prepared by the EPO or JPO.....\$930.00			
International preliminary examination fee paid to USPTO (37CFR 1.482)\$720.00			
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) . . . \$790.00			
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,070.00			
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4). \$98.00			
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$ 930.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	25-20 =	5	x \$22.00
Independent claims	3- 3 =	0	x \$82.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ \$270.00	\$
TOTAL OF ABOVE CALCULATIONS =		\$ 1,040.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).		\$	
SUBTOTAL =		\$ 1,040.00	
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +		\$	
TOTAL NATIONAL FEE =		\$ 1,040.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$ 40.00	
TOTAL FEES ENCLOSED =		\$ 1,080.00	
		Amount to be refunded:	\$
		Charged	\$1,080.00
<p>a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.</p> <p>b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>19-0091</u> in the amount of \$ <u>1,080.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0091</u>. A duplicate copy of this sheet is enclosed.</p>			
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>			
SEND ALL CORRESPONDENCE TO:			
<p>Michael D. Alexander Patent Department Sanofi Pharmaceuticals, Inc. 9 Great Valley Parkway P.O. Box 3026 Malvern, PA 19355</p>			
 SIGNATURE DATE <p><u>Michael D. Alexander</u> <u>9/17/98</u></p>			
NAME <u>Michael D. Alexander</u> 36,080 REGISTRATION NUMBER (610) 889-8802 TELEPHONE NUMBER			

09/051900
Attorney Docket No. IVD 925 D

Rec'd PCT/PTO 17 APR 1998

Application of: Loïc Foulon, Georges Garcia, Claudine Serradeil-Le Gal And
Gérard Valette

Docket No.: IVD 925 D

Filing Under U.S.C. §371

Filed as a U.S. National Phase Application of
International Application Serial No. PCT/FR96/01666
Filed: October 24, 1996

FOR: INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION
AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

CERTIFICATE UNDER 37 CFR 1.10

Express Mail Mailing Label Number _____ EH609996142US


Date Of Deposit _____ April 17, 1998

I hereby certify that this paper is being deposited with the United States Postal Service
"Express Mail Post Office To Addressee" Service on the date indicated above and is
addressed to: Assistant Commissioner For Patents, Box PCT, Attn: DO/US,
Washington, D.C. 20231



Signature and Date

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

1. Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:
 - All sheets must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
Pages _____ do not meet these requirements.
 - Papers are not flexible, strong, smooth, non-shiny, durable, and white.
 - Papers are not typewritten or mechanically printed in permanent ink on one side.
 - Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
 - Papers contain hand lettering.
2. Drawings are not in compliance and were not scanned because:
 - The drawings or copy of drawings are not suitable for electronic reproduction.
 - All drawings sheets are not either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
 - Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin of at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").
3. Page(s) _____ are not of sufficient clarity, contrast and quality for electronic reproduction.
4. Page(s) _____ are missing.
5. OTHER: No Drawings